Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.
J Cancer Res Clin Oncol. 2020 Jun;146(6):1567-1573. doi: 10.1007/s00432-020-03185-y. Epub 2020 Mar 18.
Little is known about how a gynecological cancer diagnosis affects a gynecologist's decision to prescribe hormone replacement therapy (HRT). Therefore, the goal of this study was to analyze the prevalence of HRT prescription prior to and after the diagnosis of four gynecological cancers in women followed in gynecological practices in Germany.
This study included women who were diagnosed with breast, uterine, ovarian, or vulvar cancer in 281 gynecological practices in Germany for the first time between January 2011 and December 2017. The first outcome of the study was the proportion of women with at least one HRT prescription in the year prior to and in the year after cancer diagnosis. The second outcome of the study was the proportion of gynecological practices that issued at least one HRT prescription in the year prior to and in the year after cancer diagnosis.
A total of 7189 women were included in this study. The proportion of women receiving at least one HRT prescription significantly decreased between the year prior to and the year after cancer diagnosis in the breast cancer (16.3% versus 2.3%) and the uterine cancer groups (13.4% versus 5.8%), but not in the ovarian cancer (17.6% versus 15.1%) and the vulvar cancer groups (10.8% versus 13.1%). Similar findings were obtained for the proportion of gynecological practices that issued at least one HRT prescription.
HRT prescriptions significantly decreased after the diagnosis of breast and uterine cancers but not after the diagnosis of ovarian and vulvar cancers.
关于妇科癌症诊断如何影响妇科医生开具激素替代疗法（HRT）的决定，目前知之甚少。因此，本研究的目的是分析在德国妇科实践中随访的女性中，四种妇科癌症诊断前后 HRT 处方的流行情况。
本研究纳入了 2011 年 1 月至 2017 年 12 月期间在德国 281 家妇科诊所首次被诊断为乳腺癌、子宫癌、卵巢癌或外阴癌的女性。本研究的第一个结果是在癌症诊断前一年和后一年至少有一次 HRT 处方的女性比例。本研究的第二个结果是在癌症诊断前一年和后一年至少开出一次 HRT 处方的妇科诊所比例。
本研究共纳入 7189 名女性。与癌症诊断前一年相比，乳腺癌（16.3% 比 2.3%）和子宫癌（13.4% 比 5.8%）组接受 HRT 处方的女性比例显著下降，但卵巢癌（17.6% 比 15.1%）和外阴癌（10.8% 比 13.1%）组无显著变化。至少开出一次 HRT 处方的妇科诊所比例也有类似的发现。
乳腺癌和子宫癌诊断后 HRT 处方显著减少，但卵巢癌和外阴癌诊断后 HRT 处方无显著减少。
